PARP1在可手术非小细胞肺癌组织中的表达及临床预后价值  

Expression of PARP1 in Non-Small Cell Lung Cancer and Its Prognosis Value

作　　者：王均惠 陈建新[1] 彭永海[2] 解方为[2] 

机构地区：[1]浙江大学衢州医院,浙江衢州324000 [2]中国人民解放军南京军区福州总医院,福建福州350025

出　　处：《肿瘤学杂志》2018年第1期22-26,共5页Journal of Chinese Oncology

基　　金：国家自然科学基金面上项目(81572452);福建省自然基金面上课题(2016J01579)

摘　　要：[目的]探讨PARP1在可手术非小细胞肺癌组织中的表达情况及其临床预后价值。[方法 ]采用免疫组化法对81例非小细胞肺癌患者手术标本进行PARP1蛋白表达的定量分析;运用卡方检验对PARP1表达结果与临床参数间进行比较,其中分期情况视为等级资料采用Wilcoxon秩和检验;采用Cox回归及Kaplan-Meier生存分析曲线评价PARP1对可手术非小细胞肺癌的临床预后价值。[结果]81例非小细胞肺癌患者组织样本中PARP1蛋白表达水平与性别、年龄、吸烟状况、病理类型、淋巴结转移状况等临床参数之间无统计学差异（P〉0.05）。81例患者中PARP1阳性标本中表达量为（＋）、（＋＋）、（≥＋＋＋）样本比例分别为33.33%（13/39）、35.90%（14/39）、30.77%（12/39）。Cox多因素分析结果显示,在76例具有完整生存随访资料患者中,PARP1表达情况与患者无疾病生存期相关,PARP1阴性表达组及阳性表达组DFS分别为36.2个月和23.5个月（Cox多因素分析结果 P=0.003）;但与总生存期无关,PARP1阴性表达组及阳性表达组OS分别为49.6个月和44.0个月（Cox多因素分析P=0.341）。[结论 ]PARP1阴性可手术的非小细胞肺癌患者在接受手术后可能获得较长的无疾病生存期,但可能并不能转化为总生存期上的获益。[Objective] To analyze the expression level of PARP1 in non-small cell lung cancer（NSCLC）and its prognosis value. [Methods] Immunohistochemistry was applied to detect the expression level of PARP1 in 81 NSCLC patients. The survival of patients was assessed by KaplanMeier survival curve; the relationship between PARP1 expression level and clinical characteristics and prognosis of patients was analyzed by Cox regression model. [Results] There were no correlation between the expression level of PARP1 and gender,age,smoking status,pathology subtypes,and nodal status（P0.05）. The positive expression rates of PARP1 with levels of（＋）,（＋＋）and（≥＋＋＋） were 33.3%（13/39）,35.9%（14/39） and 30.8%（12/39）,respectively. Among 71 patients with completed follow-up data,there was significant correlation between disease-free survival（DFS） and expression of PARP1：the DFS of PARP1-negative group and PARP1-positive group were 36.2 and 23.5 months,respectively（P =0.003）. However,there was no correlation between overall survival（OS） and PARP1 expression in NSCLC patients; OS of PARP1-negative group and PARP1-positive group were 49.6 and 44.0 months,respectively（P=0.341）. [Conclusion]The operable NSCLC patients with PARP1 negative may have longer DFS after surgery and adjuvant chemotherapy,while there is no correlation of PARP1 expression with OS.

关 键 词：非小细胞肺癌 ERCC1 PARP1 预后 

分 类 号：R734.2[医药卫生—肿瘤]